Allarity Therapeutics, Inc. (NASDAQ:ALLR) Short Interest Update

Allarity Therapeutics, Inc. (NASDAQ:ALLR) was the target of a significant decrease in short interest in June. As of June 30th, there was short interest totaling 80,824 shares, a decrease of 53.9% from the June 15th total of 175,384 shares. Approximately 0.5% of the company’s stock are short sold. Based on an average trading volume of 144,991 shares, the short-interest ratio is currently 0.6 days.

Allarity Therapeutics Stock Performance

Shares of NASDAQ ALLR opened at $1.18 on Thursday. Allarity Therapeutics has a fifty-two week low of $0.77 and a fifty-two week high of $2.35. The stock has a market cap of $18.77 million, a price-to-earnings ratio of -1.64 and a beta of 0.53. The firm’s 50-day simple moving average is $1.45 and its 200 day simple moving average is $1.24.

Allarity Therapeutics (NASDAQ:ALLR) last released its quarterly earnings results on Friday, May 15th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.05. The company had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.03 million. On average, sell-side analysts predict that Allarity Therapeutics will post -0.92 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on ALLR. Weiss Ratings restated a “sell (e+)” rating on shares of Allarity Therapeutics in a report on Monday, April 20th. Wall Street Zen upgraded Allarity Therapeutics to a “hold” rating in a report on Saturday, May 30th. Finally, Ascendiant Capital Markets lifted their price target on shares of Allarity Therapeutics from $9.75 to $10.25 and gave the company a “buy” rating in a research report on Monday, June 8th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $10.25.

Institutional Investors Weigh In On Allarity Therapeutics

Institutional investors have recently bought and sold shares of the stock. Private Advisor Group LLC purchased a new position in Allarity Therapeutics during the 3rd quarter worth $441,000. Renaissance Technologies LLC grew its stake in shares of Allarity Therapeutics by 274.1% in the 4th quarter. Renaissance Technologies LLC now owns 247,612 shares of the company’s stock worth $267,000 after acquiring an additional 181,426 shares in the last quarter. DRW Securities LLC purchased a new stake in shares of Allarity Therapeutics in the fourth quarter valued at about $133,000. Capital Advisors Inc. OK purchased a new stake in shares of Allarity Therapeutics in the fourth quarter valued at about $108,000. Finally, Citadel Advisors LLC bought a new position in shares of Allarity Therapeutics during the third quarter valued at about $149,000. Institutional investors own 11.53% of the company’s stock.

Allarity Therapeutics Company Profile

Allarity Therapeutics A/S (NASDAQ:ALLR) is a clinical‐stage biotechnology company focused on advancing precision medicine in oncology and other severe diseases. The company leverages predictive biomarkers and proprietary companion diagnostic tools to identify patient populations most likely to respond to its therapeutic candidates. By integrating molecular profiling early in development, Allarity aims to improve clinical trial success rates and accelerate the path to regulatory approval.

The company’s lead pipeline includes novel small‐molecule inhibitors engineered to target key pathways in solid tumors, with two primary assets currently in mid‐stage clinical trials.